ASPIVIX has announced a new partnership with AGHealth to launch Carevix, its MHRA-approved non-traumatic suction cervical stabiliser, in the United Kingdom. The company says this milestone marks a significant advance in UK women’s healthcare, offering a modern and clinically validated alternative to the traditional cervical tenaculum.
Carevix, approved for use by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), has been designed to minimise pain and reduce bleeding during intrauterine procedures such as coil-fitting and endometrial biopsies. Traditional tenaculum forceps—still commonly used—are known to cause discomfort, fear, and sometimes trauma for patients.
Peterborough City Hospital, part of the North West Anglia NHS Foundation Trust, became the first hospital in the UK to adopt Carevix in 2024 through the Carevix Ambassador Program. This initiative brought together 21 centres of excellence across 9 countries to evaluate the device in real-world settings.
Results from the program showed high satisfaction among both clinicians and patients, with 96% of clinicians finding Carevix easy to use and 94% overall patient satisfaction, according to the Carevix Ambassador Program Report 2024–2025.
Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30% to 45% of women globally, an estimated 120 million women each year, primarily due to the use of the traditional cervical tenaculum.
In addition to the Ambassador Program, the ADVANCE Women Study, a single-blinded, randomised, multicentre comparative trial, Carevix demonstrated a 73% reduction in pain and 78% reduction in bleeding during IUD placement compared to the standard tenaculum becoming a new alternative for better patient experience.
Charlotte Barker, Director of AGHealth said: “At AGHealth, we focus on delivering forward-thinking, evidence-based solutions to clinicians. Carevix represents exactly the kind of innovation the UK market needs—offering a more dignified, pain-conscious option for gynaecological procedures that women undergo every day.”
Mathieu Horras, ASPIVIX CEO & Co-Founder added: “We are proud to bring Carevix to the UK in partnership with AGHealth, a company that shares our commitment to advancing women’s health through innovation. With MHRA approval and strong clinical results, Carevix provides a game-changing solution that improves both patient comfort and clinical confidence.”
